Please assess the completion status of the following clinical trial:

Trial Title: IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. M/F patients 18 years of age or older~2. Diagnosis of ESRD (GFR ≤ 15 mL/min)~3. CAPD or APD using only Dianealand/or Physioneal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time~4. DM (Type 1 and 2) on glycemic-control medication, for 90 days~5. HbA1c \> 6.0% but ≤ 12.0%~6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL~Exclusion Criteria:~1. Cardiovascular event within the last 90 days~2. Ongoing clinically significant congestive heart failure (NYHA class III or IV)~3. Allergy to starch-based polymers~4. Glycogen storage disease~5. Maltose, or isomaltose intolerance~6. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days~7. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP \< 77) at Screening.~8. Serum urea \> 30 mmol/L~9. Exposure to Extraneal or Nutrineal within the last 60 days prior to Screening visit, Day 1.~10. Receiving rosiglitazone maleate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non glucose sparing (Type: ACTIVE_COMPARATOR): Dianeal only
- glucose sparing (Type: EXPERIMENTAL): PEN solutions: Nutrineal, Extraneal, and Physioneal

Based on this trial design, predict the completion outcome and termination type (if applicable).